TY  - JOUR
AU  - Serrano-Conde, Esther
AU  - Leyva, Alba
AU  - Fuentes, Ana
AU  - de Salazar, Adolfo
AU  - Chueca, Natalia
AU  - Perez-Castro, Sonia
AU  - Regueiro, Benito
AU  - Rojas, Almudena
AU  - Mendoza, Joaquin
AU  - Rojas, Jose
AU  - Garcia, Federico
PY  - 2021
DO  - 10.1111/tbed.14417
UR  - http://hdl.handle.net/10668/20020
T2  - Transboundary and emerging diseases
AB  - SARS-CoV-2 variation represents a serious challenge to current COVID-19 vaccines. Recent reports suggest that B.1.351 and other variants may escape the neutralization activity of the antibodies generated by current vaccines. Ninety-nine healthcare...
LA  - en
PB  - Hindawi Limited
KW  - B.1
KW  - B.1.1.7
KW  - B.1.351
KW  - BNT162b2 mRNA
KW  - SARS-CoV-2
KW  - neutralization
KW  - variants
KW  - Animals
KW  - Antibodies, Neutralizing
KW  - Antibodies, Viral
KW  - BNT162 Vaccine
KW  - COVID-19
KW  - COVID-19 Vaccines
KW  - Humans
KW  - Membrane Glycoproteins
KW  - Neutralization Tests
KW  - RNA, Messenger
KW  - SARS-CoV-2
KW  - Spike Glycoprotein, Coronavirus
KW  - Viral Envelope Proteins
TI  - In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
TY  - research article
VL  - 69
ER  -